Humanized anti-cd19 antibodies and their use in treatment of oncology, transplantation and autoimmune disease

A method of treating a B cell disease or disorder in a human comprising:

• administering to a human in need thereof a therapeutically-effective amount of an antibody,
• a) wherein said antibody is a chimeric, humanized or human monoclonal antibody or fragment thereof,
• b) wherein said antibody comprises a VH or a VL wherein said VH comprises an amino acid sequence selected from the group consisting of:
• SEQ ID NO.:
• 34, 44,102, 103, 104, 105, 106, 107, 108, 109, 191, 192, and 236,
• c) wherein said VL comprises an amino acid sequence selected from the group consisting of:
• SEQ ID NO.:
• 52, 62, 68, 70, 74, 76, 78, 80, 110, 111, 193, 194, 195, 196, 917, 198, 199, 200, 201, 202, 203, 204, 205, 206, and 207,
• d) wherein said antibody binds a human CD19 antigen, and
• e) wherein said disease or disorder is selected from a group consisting of:
• B cell malignancy, autoimmune disease, autoimmune disorder, humoral rejection in a human transplant patient, graft-versus-host disease (GVHD) and post-transplantation lymphoproliferative disorder in human transplant recipient.